ISSN: 2055-6837

Journal Home

Journal Guideline

European Heart Journal - Cardiovascular Pharmacotherapy Q1 Unclaimed

Oxford University Press United Kingdom

Unfortunately this journal has not been claimed yet. For this reason, some information may be unavailable.

European Heart Journal - Cardiovascular Pharmacotherapy is a journal indexed in SJR in Cardiology and Cardiovascular Medicine and Pharmacology (medical) with an H index of 40. It has an SJR impact factor of 1,507 and it has a best quartile of Q1. It has an SJR impact factor of 1,507.

Type: Journal

Type of Copyright:

Languages:

Open Access Policy:

Type of publications:

Publication frecuency: -

Categories: Cardiology and Cardiovascular Medicine (Q1) Pharmacology (medical) (Q1)

Price

- €

Inmediate OA

NPD

Embargoed OA

- €

Non OA

Metrics

European Heart Journal - Cardiovascular Pharmacotherapy

1,507

SJR Impact factor

40

H Index

94

Total Docs (Last Year)

329

Total Docs (3 years)

2657

Total Refs

1095

Total Cites (3 years)

203

Citable Docs (3 years)

3.62

Cites/Doc (2 years)

28.27

Ref/Doc

Comments

No comments ... Be the first to comment!

Publication speed *

Review quality *

Edition and editorial team *

Institutional email or ORCID *

* The email or ORCID field is only to validate the authenticity of the comment, the identity will not be public. .

Other journals with similar parameters

Journal of the American College of Cardiology Q1
Circulation Q1
Nature Reviews Cardiology Q1
JAMA Cardiology Q1
European Journal of Heart Failure Q1

Compare this journals

Aims and Scope

Best articles by citations

Contemporary use of ticagrelor in patients with acute coronary syndrome: insights from Swedish Web System for Enhancement and Development of Evidence-Based Care in Heart Disease Evaluated According to Recommended Therapies (SWEDEHEART)

Development of triglyceride-lowering drugs to address residual cardiovascular risk: strategic and clinical considerations

Gender differences in the effects of cardiovascular drugs

The role of trimetazidine in cardiovascular disease: beyond an anti-anginal agent

Ivabradine for heart failure: regulatory differences in Europe and United States

Changing paradigms in oral anticoagulation during cardioversion in Europe

Congestive heart failure: More common as well as an important cardiovascular outcome - reply

SGLT1 does compensate for SGLT2 inhibition

Editorial on PEGASUS-TIMI 54

Anticoagulation in COVID-19

Glycemic control and acute coronary syndrome: the debate continues

Starting up a new Journal within theEuropean Heart JournalFamily

SHOW MORE ARTICLES

Long-term antiarrhythmic drug treatment after atrial fibrillation ablation: does a too obstinate rhythm control strategy bring serious risk of proarrhythmia to ablated patients?

Update from EHJ CVP

Second year of a journal

Pre-admission use of platelet inhibitors and short-term stroke mortality: a population-based cohort study

Patients with atrial fibrillation and diabetes: does apixaban remain the drug of choice?

Cardio-renal protection through renin-angiotensin-aldosterone system inhibition: current knowledge and new perspectives

Non-steroidal anti-inflammatory drugs and incident atrial fibrillation

Editorial Comment for the "Risk of Thrombocytopenia with Glycoprotein IIb/IIIa Inhibitors across Drugs and Patient Populations: a Meta-Analysis of 29 Large Placebo-Controlled Randomized Trials". Thrombocytopenia as an important complication with the

Editorial comment on 'A novel approach indirectly comparing benefit: risk across oral antithrombotic therapies in patients with atrial fibrillation'. Are the evidences of current dose-adjusted anticoagulation with warfarin stroke prevention for patie

Adjunctive use of anticoagulants at the time of percutaneous coronary intervention in patients with an acute coronary syndrome treated with fondaparinux: a multinational retrospective review

Renal sympathetic denervation after Symplicity HTN-3 and therapeutic drug monitoring in patients with resistant hypertension to improve patients' adherence

Medical misinformation: vet the message!